-
Himalaya Amalaki Tablets
x1 - ₹265.00 -
Himalaya Arjuna Tablets
x1 - ₹270.00 -
Baidyanath Mall Tail
x1 - ₹687.00
View Cart Checkout
Baidyanath Triphala Churna
Price range: ₹12.95 through ₹24.95
Product Description
Baidyanath Triphala Churna
Acts as an alternative & mild laxative. Tones up the function of digestive system by relieving the constipation associated with it like loss of appetite, heaviness in abdomen etc. Indicated in eye diseases.
Therapatic Uses of Baidyanath Triphala Churna :
- Useful in Dyspepsia, Diarrhoea, Piles, Impurity Of Blood Irritation in Eye and Haemorrhage.
Composition (Each 10gm Baidyanath Triphala Churna contains) :
- Haritaki – 3.333gm
- Bibhitaka – 3.333 gm
- Amalaki – 3.333gm
Dosage of Baidyanath Triphala Churna :
2-3 teaspoonful at bed time with water or butter milk.
Additional Information
| Quantity | 120g (2 x 60g), 240g (4 x 60g), 480g (8 x 60g) |
|---|
Be the first to review “Baidyanath Triphala Churna”
Related Products
Baidyanath Maha Manjishthadyarishta
Price range: ₹22.45 through ₹55.95
Select options
This product has multiple variants. The options may be chosen on the product page
Baidyanath Musli PakVyas Vigojem TabletBaidyanath Musli Pak
Original price was: ₹270.00.₹250.00Current price is: ₹250.00.
Baidyanath Madiphal Rasayanam
₹14.95
Select options
This product has multiple variants. The options may be chosen on the product page
Baidyanath Kanchnar Guggulu Tablets
Original price was: ₹134.00.₹120.00Current price is: ₹120.00.
Baidyanath Mall Tail
Original price was: ₹764.00.₹687.00Current price is: ₹687.00.
Baidyanath Ashokarishta
₹25.95
Select options
This product has multiple variants. The options may be chosen on the product page
Baidyanath Draksharishta
Price range: ₹22.95 through ₹55.45
Select options
This product has multiple variants. The options may be chosen on the product page
Baidyanath Dashmoolarista
Price range: ₹22.95 through ₹55.45
Select options
This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.